Literature DB >> 17473847

Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women.

X Fan1, Y Wang, K Sun, W Zhang, X Yang, S Wang, Y Zhen, J Wang, W Li, Y Han, T Liu, X Wang, J Chen, H Wu, R Hui.   

Abstract

ACE2 appears to counterbalance the vasopressor effect of angiotensin I converting enzyme (ACE) in the reninangiotensin system. We hypothesized that ACE2 polymorphisms could confer a high risk of hypertension and have an impact on the antihypertensive response to ACE inhibitors. The hypothesis was tested in two casecontrol studies and a clinical trial of 3,408 untreated hypertensive patients randomized to Atenolol, Hydrochlorothiazide, Captopril, or Nifedipine treatments for 4 weeks. ACE2 rs2106809 T allele was found to confer a 1.6-fold risk for hypertension in women (95% confidence interval (CI), 1.132.06), whereas when combined with the effect of the ACE DD genotype, the risk was 2.34-fold (95% CI, 1.754.85) in two independent samples. The adjusted diastolic blood pressure response to Captopril was 3.3 mm Hg lower in ACE2 T allele carriers than in CC genotype carriers (P=0.019) in women. We conclude that the ACE2 T allele confers a high risk for hypertension and reduced antihypertensive response to ACE inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473847     DOI: 10.1038/sj.clpt.6100214

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  44 in total

1.  Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7).

Authors:  Carlos M Ferrario; Sarfaraz Ahmad; Janae Joyner; Jasmina Varagic
Journal:  Adv Pharmacol       Date:  2010

Review 2.  Angiotensin-converting enzymes and drug discovery in cardiovascular diseases.

Authors:  Lijun Shi; Caiping Mao; Zhice Xu; Lubo Zhang
Journal:  Drug Discov Today       Date:  2010-02-17       Impact factor: 7.851

3.  Clinical impact of echocardiography parameters and molecular biomarkers in heart failure: Correlation of ACE2 and MCP-1 polymorphisms with echocardiography parameters: A comparative study.

Authors:  Mălina Suciu-Petrescu; Anamaria Truta; Mihai Domnutiu Suciu; Adrian Pavel Trifa; Denisa Petrescu; Horia Ștefan Roșianu; Octavia Sabin; Daciana Elena Popa; Antonia Eugenia Macarie; Ștefan Cristian Vesa; Anca Dana Buzoianu
Journal:  Exp Ther Med       Date:  2021-04-28       Impact factor: 2.447

4.  Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study.

Authors:  Carly Welch
Journal:  Age Ageing       Date:  2021-05-05       Impact factor: 10.668

5.  Impact of ACE2 deficiency and oxidative stress on cerebrovascular function with aging.

Authors:  Ricardo A Peña Silva; Yi Chu; Jordan D Miller; Ian J Mitchell; Josef M Penninger; Frank M Faraci; Donald D Heistad
Journal:  Stroke       Date:  2012-11-15       Impact factor: 7.914

6.  The reference human genome demonstrates high risk of type 1 diabetes and other disorders.

Authors:  Rong Chen; Atul J Butte
Journal:  Pac Symp Biocomput       Date:  2011

7.  The High Blood Pressure-Malaria Protection Hypothesis.

Authors:  Julio Gallego-Delgado; Thomas Walther; Ana Rodriguez
Journal:  Circ Res       Date:  2016-09-22       Impact factor: 17.367

Review 8.  Genetic determinants of hypertension: an update.

Authors:  Michael Harrison; Karen Maresso; Ulrich Broeckel
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 9.  Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.

Authors:  Amber L Beitelshees; Issam Zineh
Journal:  Heart Fail Rev       Date:  2008-03-20       Impact factor: 4.214

10.  Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors.

Authors:  Y Y Chen; D Liu; P Zhang; J C Zhong; C J Zhang; S L Wu; Y Q Zhang; G Z Liu; M He; L J Jin; H M Yu
Journal:  J Hum Hypertens       Date:  2016-04-28       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.